Volume 15, Issue 4, Pages 464-473 (April 2014) Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long- term results from the MRC RT01 randomised controlled trial  Prof David P Dearnaley, FRCR, Gordana Jovic, PhD, Isabel Syndikus, FRCR, Vincent Khoo, FRCR, Richard A Cowan, FRCR, John D Graham, FRCR, Edwin G Aird, PhD, David Bottomley, FRCR, Robert A Huddart, FRCR, Chakiath C Jose, FRANZCR, John H L Matthews, FRANZCR, Jeremy L Millar, FRANZCR, Claire Murphy, BSc, J Martin Russell, FRCR, Christopher D Scrase, FRCR, Prof Mahesh K B Parmar, DPhil, Matthew R Sydes, MSc  The Lancet Oncology  Volume 15, Issue 4, Pages 464-473 (April 2014) DOI: 10.1016/S1470-2045(14)70040-3 Copyright © 2014 Dearnaley et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 1 Trial profile The Lancet Oncology 2014 15, 464-473DOI: (10.1016/S1470-2045(14)70040-3) Copyright © 2014 Dearnaley et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 2 Primary analysis of overall survival and biochemical progression-free survival (A) Overall survival, predicted from Kaplan-Meier function and flexible parametric model. (B) Absolute difference in overall survival, from flexible parametric model. (C) Biochemical progression-free survival, predicted by Kaplan-Meier function and flexible parametric model. (D) Absolute difference in biochemical progression-free survival, from flexible parametric model. The Lancet Oncology 2014 15, 464-473DOI: (10.1016/S1470-2045(14)70040-3) Copyright © 2014 Dearnaley et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 3 Subgroup analyses of overall survival and biochemical progression-free survival (A) Overall survival and risk of seminal vesicle involvement. (B) Overall survival and National Comprehensive Cancer Network risk group. (C) Biochemical progression-free survival and risk of seminal vesicle involvement. (D) Biochemical progression-free survival and National Comprehensive Cancer Network risk group. HR=hazard ratio. The Lancet Oncology 2014 15, 464-473DOI: (10.1016/S1470-2045(14)70040-3) Copyright © 2014 Dearnaley et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 4 Additional outcome measures (A) Progression-free survival, Kaplan-Meier plot. (B) Initiation of ADT, Kaplan-Meier plot. (C) Metastases-free survival, Kaplan-Meier plot. (D) Cumulative incidence of PC deaths and non-PC deaths. ADT=androgen deprivation therapy. PC=prostate cancer. The Lancet Oncology 2014 15, 464-473DOI: (10.1016/S1470-2045(14)70040-3) Copyright © 2014 Dearnaley et al. Open Access article distributed under the terms of CC BY Terms and Conditions